Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
4317-14-0
Molecular formula
C20H23NO
Molecular weight
293.4 g/mol
Drug class
Tricyclic antidepressant-related N-oxidenoradrenergic and serotonergic reuptake inhibitor (historical)
Mechanism of action
Amitriptylinoxide is related to amitriptyline and is metabolised to active tricyclic antidepressant species. The pharmacology is associated with inhibition of serotonin and noradrenaline reuptake and antagonism at histamine, muscarinic and alpha-adrenergic receptors; current clinical mechanism and availability are limited.
Indications / reported uses
Historical treatment of depressive disorders in countries where amitriptylinoxide products were authorised; current marketed status and indications require local verification
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Amitriptylinoxide Environmental Risk Assessment (ERA) (the Amitriptylinoxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.